About
Tolremo develops orally available small molecule inhibitors targeting transcriptional non-oncogene addiction to overcome drug resistance in cancer, with a lead candidate TT125-802 focused on treating solid tumors and hematological malignancies.
Explore Tolremo's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.